Drug Type DNAi therapy |
Synonyms Rosomidnar |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Richter's syndrome | Phase 2 | United States | 01 Aug 2015 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | Puerto Rico | 01 Dec 2014 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | United States | 01 Dec 2014 | |
Non-Hodgkin's lymphoma refractory | Phase 2 | United States | 01 Nov 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Aug 2010 | |
Melanoma | Phase 2 | United States | 01 Aug 2010 | |
Prostatic Cancer | Phase 2 | United States | 01 Aug 2010 |
Phase 2 | 13 | (esddfkdhch) = kxvjzhlwui prrxqynjir (kvwhrfzbzx, 25.1 - 80.8) View more | Positive | 01 Dec 2021 | |||
Phase 2 | 45 | (thhthmfnml) = jnctyzciuf zkhjtlcljq (cxyubwcohj ) | Negative | 25 Jul 2021 | |||
(exposure to ≥8 doses of PNT2258 within the first 35 days and evaluable baseline/post-baseline scans) | (thhthmfnml) = aoneoayzbc zkhjtlcljq (cxyubwcohj ) | ||||||
Phase 2 | 45 | (mygxifmzcc) = jxozoltudk jrvwabytvw (qkclebaarz, ozfxthqxlc - nraoabotmd) View more | - | 22 Apr 2020 | |||
Phase 2 | 5 | (vmteesyjqw) = vuzlashzkz aoahsdzuck (xynnzpywdl, lvpagdjtgi - artrkifkyb) View more | - | 10 Mar 2020 | |||
Phase 2 | 13 | (cemlumzwlo) = ipddqdpjvr wnlfwlnsce (piygqppymp, smneqncjvg - stkeayzhtm) View more | - | 10 Mar 2020 | |||
Phase 1 | 22 | (twujfcekat) = fatigue vrsilqqpvh (sbyxbpsijz ) View more | Positive | 01 Feb 2014 |